ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33432027

about

Epigenetics in cancer stem cells.Entinostat for the treatment of breast cancer.Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity.

P2860

Q37618640-C7CF60D4-5999-4F2E-ADC9-C3E6FA96C4B5 Q38674317-E8EFA308-951E-47A7-A9F0-45772F8265D7 Q47610009-B709D2FF-972C-4352-9268-0767D0FD9B6D

P2860

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33432027

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@ast

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@en

type

label

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@ast

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@en

prefLabel

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@ast

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@en

P1433

Q33432027-9585CC41-2BEA-42FD-BE92-8D9DF564D2CA

P1476

Q33432027-83AB7E71-C4E6-486E-88BD-5619F653ED98

P2093

Q33432027-2B93FD00-494C-437C-8DDB-8E69AB9BF9F5

Q33432027-385A43FE-BC54-4F67-AB4E-64DE3BB8C40D

Q33432027-445FFEA6-AAE0-4278-88E5-02E7DE53E8B5

Q33432027-4DCF0789-0AD9-48DB-950C-8A38F024D05B

Q33432027-6DC98E68-B417-4B23-917D-A8037BB08152

Q33432027-713C9DE6-45DD-4EE3-8EEC-B06612121A6A

Q33432027-7FAC161E-C049-4A38-A098-FFA237F699F8

Q33432027-96B43181-9F1A-40BC-A22F-A44271875728

Q33432027-B20B9A52-6DC9-4831-A1AF-11AEE8E67928

Q33432027-C761AAB7-14F3-48D3-9200-BF0B27F7786C

P2860

Q33432027-0A0499CA-E63B-415B-8A87-414AA4B31E08

Q33432027-0A49C2D3-783A-45D5-87F7-FD1292D9593F

Q33432027-2C36E641-0FAC-4427-B6E5-8F544B87D154

Q33432027-4D23634E-05EF-4019-817F-84AD23CB1E6B

Q33432027-53768567-5BC2-4816-BCAC-5289E656E66D

Q33432027-55E985CF-370E-47A4-BE2C-57069681D35E

Q33432027-67F9DCBC-4C56-4B22-AB96-B4B2EF3AD430

Q33432027-6AF30AD6-317E-4213-9921-5B2CF924A6BD

Q33432027-7101C42D-2B96-4667-8F45-BF9AB93B5C09

Q33432027-74916134-FA3A-4D9A-A23E-F98A866A8863

P304

Q33432027-573E4E2E-E25B-4DFE-AD07-26CE5ACCD0BF

P31

Q33432027-49A2E61A-EAA2-403B-A1D9-ED8CFDD0DC17

P356

Q33432027-F57FAC57-0DD3-4818-8D14-88DCB9900F6B

P433

Q33432027-FFB47395-9C89-46E3-995E-E43B9F257F02

P478

Q33432027-70F3CA8F-9494-4F11-9580-51A360B1B6E6

P577

Q33432027-0822A337-0AAD-4B31-A88A-E04EADEEB0CF

P698

Q33432027-193D11C3-9392-434C-8EED-C6570BE81194

P921

Q33432027-C3EBB641-844D-4660-9B34-48351E47CCFD

P932

Q33432027-36649E4C-9E74-4A27-9A9B-2AF97A15538C

P356

HAEMATOL.2016.142406

P1433

P1476

ENGAGE- 501: phase II study of ...... d refractory Hodgkin lymphoma.

@en

P2093

Amanda Copeland

http://www.w3.org/2001/XMLSchema#string

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Connie Lee Batlevi

http://www.w3.org/2001/XMLSchema#string

Daniela Buglio

http://www.w3.org/2001/XMLSchema#string

Francisco Hernandez-Ilizaliturri

http://www.w3.org/2001/XMLSchema#string

Lia Gore

http://www.w3.org/2001/XMLSchema#string

Lori Kunkel

http://www.w3.org/2001/XMLSchema#string

Peter Lee

http://www.w3.org/2001/XMLSchema#string

Peter Ordentlich

http://www.w3.org/2001/XMLSchema#string

R Gregory Bociek

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

P304

968-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.142406

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27151994

http://www.w3.org/2001/XMLSchema#string

P921

P932

4967576

http://www.w3.org/2001/XMLSchema#string